Optimizing Immune Checkpoint Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer
Jun 30, 2022•13 min•Ep. 60
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this episode, Sandip Patel, MD shares his thoughts on optimizing immune checkpoint inhibitor (ICI) therapy in advanced non-small-cell lung cancer (NSCLC) and discusses best practices for individualizing therapy decisions and managing adverse events.
Topics include:
- Currently approved ICIs
- Role of biomarker and PD-L1 testing in advanced NSCLC
- Strategies to individualize ICI treatment for patients with advanced NSCLC
- Strategies for identifying and managing immune-related adverse events in patients treated with ICI
Presenter:
Sandip P. Patel, MD
Associate Professor
Department of Medicine
Division of Hematology/Oncology
University of California – San Diego
La Jolla, California
Link to full program:
https://bit.ly/39vuCHC
For the best experience, listen in Metacast app for iOS or Android